Drug Screening Identifies Bavisant as Promising Multiple Sclerosis Treatment

Multiple sclerosis affects millions worldwide by destroying the protective myelin sheaths around nerve fibers, leading to progressive disability. Current treatments primarily suppress immune attacks but fail to repair existing damage or protect neurons from degeneration.

Researchers developed an innovative approach combining artificial intelligence screening with comprehensive laboratory validation. They analyzed over 1,500 existing drugs using computer models to predict effects on nerve repair and protection, narrowing the field to 273 promising candidates.

Through rigorous testing in rodent and human cell cultures, scientists identified 32 compounds showing both myelin-promoting and neuroprotective properties. Bavisant, a histamine H3 receptor antagonist, emerged as the top candidate. In multiple mouse models replicating MS pathology, bavisant consistently promoted remyelination and prevented nerve cell death.

The drug demonstrated efficacy across various injury types, including chemical demyelination, toxin-induced damage, and autoimmune models. Importantly, bavisant worked in humanized mouse models using actual human brain cells, suggesting strong translational potential.

For longevity and brain health, this research represents a paradigm shift toward regenerative neurotherapies. Rather than merely slowing disease progression, bavisant actively repairs damage and protects remaining healthy tissue. This dual mechanism could potentially benefit other neurodegenerative conditions involving myelin loss.

While promising, these remain preclinical findings requiring human trials to confirm safety and efficacy. The drug repurposing approach offers advantages in accelerated development timelines and established safety profiles.